Day: December 9, 2019

LiiteLAT1V_9.12_trades

09.12.2019 at 18:30UNITED BANKERS CORPORATION: ACQUISITION OF OWN SHARES 09.12.2019The shares held by United Bankers Corporation on 09.12.2019:On behalf of United Bankers CorporationAntti Salakka         Mikko VirtanenFor more information, please contact:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiAttachmentUB SBB 09122019

 09.12.2019 klo 18:30 UNITED BANKERS OYJ:n OMIEN OSAKKEIDEN HANKINTA 09.12.2019Yhtiön hallussa olevat omat osakkeet 09.12.2019:  United Bankers Oyj:n puolesta  Antti Salakka         Mikko Virtanen Lisätietoja antaa:Patrick Anderson, toimitusjohtaja, United Bankers OyjSähköposti: patrick.anderson@unitedbankers.fiPuhelin: 0400 244 544,09 25 380 236www.unitedbankers.fiLiiteUB SBB 09122019

88% ORR, 61% CR rate by IWG criteria in 33 evaluable MDS patients8.4 months median duration of response, with 7.3 months median duration of CR in evaluable MDS patients52% of evaluable MDS patients discontinued treatment for stem cell transplantBOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) — Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented results at the 2019 ASH Annual Meeting from its U.S. Phase Ib/II clinical trial in MDS and AML. The trial is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of TP53 mutated MDS and AML. The clinical trial is sponsored by the Moffitt Cancer Center with financial support from the MDS Foundation and the Aplastic...

74% ORR, 66% CR rate in 24 evaluable MDS patientsMedian duration of follow-up is 6.4 monthsBOSTON, Dec. 09, 2019 (GLOBE NEWSWIRE) —  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate mutant tumor suppressor protein p53, presented preliminary results at the 2019 ASH Annual Meeting from its French Phase Ib/II clinical trial in MDS and AML. The trial is evaluating the safety and efficacy of APR-246 in combination with azacitidine for the treatment of patients with TP53 mutated MDS and AML. The clinical trial is sponsored by the Groupe Francophone des Myélodysplasies.As of the data cutoff, the overall response rate (ORR) in 24 evaluable MDS patients was 74%, with a 66% complete remission (CR) rate, based on International Working Group...

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)All interests and all short positions should be disclosed.Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should...

AUSTIN, Texas, Dec. 09, 2019 (GLOBE NEWSWIRE) — Asure Software (NASDAQ:ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, was recently recognized as one of North America’s Fastest Growing Companies on Deloitte’s 2019 Technology Fast 500™.Now in its 25th year, the award features the 500 fastest growing technology, media, telecommunications, life sciences, and energy tech companies in North America based on percentage fiscal year revenue growth over a three year period. Asure Software grew 231 percent during this period.  Asure’s fully-integrated HCM platform, flexible benefits and compliance administration, HR consulting, and time and labor management solutions are used by over 60,000 customers.Asure Software’s chief executive officer, Pat Goepel, attributes the company’s consistent revenue...

Largo, FL, Dec. 09, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Today, Leone Asset Management (OTC PINK: LEON) announced the closing of the acquisition with BFA Media, Inc. (Terms were not disclosed.)James Price, CEO of Leone Asset Management, stated, “We are extremely excited to announce the closing with BFA Media.  We believe the BFA acquisition will bring tremendous shareholder value to Leone as well as add great exposure to Go Epic Health’s flagship product Cholesterade® and other products and services we own or partner with.”About Leone Asset Management Leone Asset Management, Inc., is a multi-national, multi-industry conglomerate with subsidiary companies that operate in Health and Wellness, Media & Communications, Infrastructure development, agriculture management and mining exploration. For additional information,...